AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1955308 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20
Study 1955308 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg yohimbine per os
Number of subjects: 20
Study 1955308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6763456 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 0
Study 6763456 — intervention group
Group type: COMPARATOR
Intervention: Conray 60 (iothalamate meglumine)
Number of subjects: 0
Study 30862384 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 24
Study 30862384 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 24
Study 30862384 — intervention group
Group type: COMPARATOR
Intervention: Both PTNS and TTNS
Number of subjects: 24
Study 29883769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omega-3 (ω3) supplementation
Number of subjects: 0
Study 26293358 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunted heart rate response (HRR) to regadenoson stress myocardial perfusion imaging (MPI)
Number of subjects: 303
Study 26293358 — intervention group
Group type: COMPARATOR
Intervention: Normal heart rate response (HRR) to regadenoson stress myocardial perfusion imaging (MPI)
Number of subjects: 303
Study 24914003 — intervention group
Group type: EXPERIMENTAL
Intervention: Soapy water (30 g powdered detergent in 1.5 L water)
Number of subjects: 0
Study 24914003 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar soap
Number of subjects: 0
Study 24914003 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 0
Study 21993999 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alerts recommending performance of an electrocardiogram and administration of aspirin for high risk patients (FRS ≥ 10%)
Number of subjects: 7083
Study 21993999 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic alerts recommending against performance of cardiac stress testing for low risk patients (FRS < 10%)
Number of subjects: 7083
Study 21993999 — intervention group
Group type: COMPARATOR
Intervention: High risk patients evaluated in the emergency department
Number of subjects: 7083
Study 21993999 — intervention group
Group type: COMPARATOR
Intervention: High risk patients hospitalized
Number of subjects: 7083
Study 21993999 — intervention group
Group type: COMPARATOR
Intervention: Acute myocardial infarction occurrence
Number of subjects: 7083
Study 19755409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 12
Study 19755409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17324155 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (LDD) for 3 months
Number of subjects: 34
Study 17324155 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) for 3 months
Number of subjects: 34
Study 15210651 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype hypertensive subjects
Number of subjects: 140
Study 15210651 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/AG genotype hypertensive subjects
Number of subjects: 140
Study 11390534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 6262
Study 9715839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute methadone treatment
Number of subjects: 8
Study 9715839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic methadone treatment
Number of subjects: 8
Study 7978183 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 51
Study 7978183 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 51
Study 7978183 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 51
Study 2491026 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 60
Study 2491026 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 60
Study 1107769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol slow-release formulation (Aptin Durules) 400-800 mg per day
Number of subjects: 0
Study 1107769 — intervention group
Group type: COMPARATOR
Intervention: Alprenolol ordinary tablets (Aptin) 400 mg per day
Number of subjects: 0
Study 1107769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol slow-release formulation (Aptin Durules) double dosage
Number of subjects: 0
Study 31464960 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (1 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Number of subjects: 196
Study 31464960 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (0.5 μg·kg for 10 minutes, then adjusted to 0.2‐0.7 μg·kg·hour)
Number of subjects: 196
Study 31464960 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.3 μg·kg for 10 minutes, then adjusted to 0.2‐0.4 μg·kg·hour)
Number of subjects: 196
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: MET overexpression (IHC 3+)
Number of subjects: 816
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 overexpression (IHC 3+)
Number of subjects: 816
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: MET overexpression in HER2 positive patients
Number of subjects: 816
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MET overexpression and clinical stages
Number of subjects: 816
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between MET overexpression and pathologic stages
Number of subjects: 816
Study 28052014 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance rate between MET overexpression and gene amplification
Number of subjects: 816
Study 26583670 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular lymph node involvement (EC‐LNI)
Number of subjects: 1639
Study 26583670 — intervention group
Group type: COMPARATOR
Intervention: Intracapsular lymph node involvement (IC‐LNI)
Number of subjects: 1639
Study 26583670 — intervention group
Group type: COMPARATOR
Intervention: pN1 IC‐LNI
Number of subjects: 1639
Study 26583670 — intervention group
Group type: EXPERIMENTAL
Intervention: pN1 EC‐LNI
Number of subjects: 1639
Study 26583670 — intervention group
Group type: EXPERIMENTAL
Intervention: pN2 EC‐LNI
Number of subjects: 1639
Study 26583670 — intervention group
Group type: EXPERIMENTAL
Intervention: pN3 EC‐LNI
Number of subjects: 1639
Study 24127952 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vaginal progesterone daily until delivery
Number of subjects: 52
Study 24127952 — intervention group
Group type: COMPARATOR
Intervention: No therapy or placebo
Number of subjects: 52
Study 21981704 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori intervention
Number of subjects: 29
Study 21981704 — intervention group
Group type: COMPARATOR
Intervention: Routine activities
Number of subjects: 29
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) WBC count > or = 102 cells/microL
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (IL-10) concentrations > or = 37 pg/mL
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: LATEX/IgM end titers > or = 1:32
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: LATEX/T. b. gambiense end titers > or = 1:2
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total protein concentrations > or = 674 mg/L
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF WBC counts < or = 5 cells/microL (6 months after treatment)
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (12 months after treatment)
Number of subjects: 260
Study 18494605 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF WBC count > or = 8 cells/microL and LATEX/IgM end titer > or = 1:4 (18 and 24 months after treatment)
Number of subjects: 260
Study 17002722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose) plus iron supplements (60 mg elemental iron daily)
Number of subjects: 1042
Study 17002722 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus iron supplements
Number of subjects: 1042
Study 12690946 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied muscle tension after watching a 2-min instructional video
Number of subjects: 37
Study 12690946 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied muscle tension
Number of subjects: 37
Study 12690946 — intervention group
Group type: COMPARATOR
Intervention: Untreated donors
Number of subjects: 37
Study 12690946 — intervention group
Group type: COMPARATOR
Intervention: More experienced blood donors
Number of subjects: 37
Study 10932486 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12
Study 10932486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8966351 — intervention group
Group type: EXPERIMENTAL
Intervention: dehydrobenzperidol (1.25 mg)
Number of subjects: 100
Study 8966351 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide (10 mg)
Number of subjects: 100
Study 8966351 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 100
Study 8966351 — intervention group
Group type: COMPARATOR
Intervention: placebo (2 ml saline)
Number of subjects: 100
Study 1342886 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized, freeze-dried DP extract in powder (active therapy)
Number of subjects: 24
Study 1342886 — intervention group
Group type: COMPARATOR
Intervention: Lactose capsules (placebo group)
Number of subjects: 24
Study 3871188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 25
Study 3871188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg
Number of subjects: 25
Study 3871188 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) aerosol 336 micrograms
Number of subjects: 25
Study 3871188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 3871188 — intervention group
Group type: COMPARATOR
Intervention: BDP vehicle
Number of subjects: 25
Study 31798892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylamine N-oxide (TMAO) levels
Number of subjects: 330
Study 31798892 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched by age, sex, and treatment arm)
Number of subjects: 330
Study 30096932 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural Therapy (HT)
Number of subjects: 59
Study 30096932 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 59
Study 27348909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with moxibustion plaster
Number of subjects: 60
Study 27348909 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 24825870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 312
Study 24825870 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 312
Study 24825870 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis
Number of subjects: 312
Study 22189593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (FP) 100 mcg twice daily as initial treatment with Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as additional treatment
Number of subjects: 51
Study 22189593 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine hydrochloride tablet (FEX) 60 mg twice daily as initial treatment with Fluticasone propionate nasal spray (FP) 100 mcg twice daily as additional treatment
Number of subjects: 51
Study 20348976 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain used in group A (35 patients)
Number of subjects: 67
Study 20348976 — intervention group
Group type: COMPARATOR
Intervention: No drain used in group B (32 patients)
Number of subjects: 67
Study 18388769 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine fossa puncture (CFP)
Number of subjects: 24
Study 18388769 — intervention group
Group type: COMPARATOR
Intervention: Maxillary sinus clearance through middle meatal antrostomy (MMA)
Number of subjects: 24
Study 16092049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with poorly controlled diabetes
Number of subjects: 28
Study 16092049 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control)
Number of subjects: 28
Study 12410456 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain suction
Number of subjects: 116
Study 12410456 — intervention group
Group type: COMPARATOR
Intervention: No drain suction
Number of subjects: 116
Study 12410456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 10511346 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estradiol‐progestogen (2 mg estradiol + 0.5 mg trimegestone or 10 mg dydrogesterone)
Number of subjects: 59
Study 10511346 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estradiol (2 mg)
Number of subjects: 59
Study 10511346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7495242 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐carotene, alpha‐tocopherol, and selenium
Number of subjects: 30000
Study 7495242 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple vitamin‐mineral supplementation
Number of subjects: 30000
Study 1742667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatable pulmonary artery banding prosthesis
Number of subjects: 19
Study 1742667 — intervention group
Group type: COMPARATOR
Intervention: Fixed fabric bands
Number of subjects: 19
Study 7176845 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 148
Study 7176845 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 148
Study 7176845 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive treatment
Number of subjects: 148
Study 31621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug
Number of subjects: 1759
Study 31621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals with a history of suicidal behavior
Number of subjects: 1759
Study 31621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals without a history of suicidal behavior
Number of subjects: 1759
Study 31621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals with a familial predisposition to psychiatric disorders
Number of subjects: 1759
Study 31621936 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of any antiepileptic drug in individuals without a familial predisposition to psychiatric disorders
Number of subjects: 1759
Study 27672124 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04236921 10 mg
Number of subjects: 183
Study 27672124 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04236921 50 mg
Number of subjects: 183
Study 27672124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 27672124 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04236921 200 mg
Number of subjects: 183
Study 25930037 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 1622
Study 25930037 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 1622
Study 23968157 — intervention group
Group type: COMPARATOR
Intervention: CHF5074 (600 mg/day)
Number of subjects: 96
Study 23968157 — intervention group
Group type: COMPARATOR
Intervention: CHF5074 (200 mg/day)
Number of subjects: 96
Study 23968157 — intervention group
Group type: COMPARATOR
Intervention: CHF5074 (400 mg/day)
Number of subjects: 96
Study 23968157 — intervention group
Group type: EXPERIMENTAL
Intervention: CHF5074 (dose-dependent)
Number of subjects: 96
Study 21849078 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 0
Study 21849078 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 0
Study 19142656 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) and Glycerol (Gly) supplementation (20 g Cr and 2 g Gly per kg body mass plus 2 l of water)
Number of subjects: 19
Study 19142656 — intervention group
Group type: COMPARATOR
Intervention: Water alone (Pl)
Number of subjects: 19
Study 16489526 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m(2)) and autologous blood stem-cell support
Number of subjects: 6
Study 16489526 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) alone
Number of subjects: 6
Study 16489526 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (2-4 g/m(2)) and rhG-CSF
Number of subjects: 6
Study 15291211 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support group
Number of subjects: 24
Study 15291211 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational support group
Number of subjects: 24
Study 15291211 — intervention group
Group type: COMPARATOR
Intervention: No-support group (control)
Number of subjects: 24
Study 10932515 — intervention group
Group type: EXPERIMENTAL
Intervention: DM‐T (n = 7)
Number of subjects: 61
Study 10932515 — intervention group
Group type: COMPARATOR
Intervention: DM‐C (n = 21)
Number of subjects: 61
Study 9032543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabal serrulata extract IDS 89 (Strogen) 320 mg/capsule, 3 x 2 capsules daily for 3 months
Number of subjects: 18
Study 9032543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8495772 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF treatment (one cycle)
Number of subjects: 245
Study 8495772 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait for 6 months before IVF)
Number of subjects: 245
Study 2825571 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 79
Study 2825571 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 31786367 — intervention group
Group type: EXPERIMENTAL
Intervention: High vowel overlap training (e.g., EA, AI)
Number of subjects: 361
Study 31786367 — intervention group
Group type: COMPARATOR
Intervention: Low vowel overlap training (e.g., EE, AI)
Number of subjects: 361
Study 31786367 — intervention group
Group type: EXPERIMENTAL
Intervention: Consonant variability manipulation
Number of subjects: 361
Study 29844205 — intervention group
Group type: EXPERIMENTAL
Intervention: BuFlu
Number of subjects: 1781
Study 29844205 — intervention group
Group type: COMPARATOR
Intervention: BuCy
Number of subjects: 1781
Study 28122649 — intervention group
Group type: EXPERIMENTAL
Intervention: L- and MZ-enriched eggs
Number of subjects: 0
Study 28122649 — intervention group
Group type: COMPARATOR
Intervention: Control non-enriched eggs
Number of subjects: 0
Study 28122649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (enriched and control)
Number of subjects: 0
Study 25692545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosep device
Number of subjects: 53
Study 25692545 — intervention group
Group type: COMPARATOR
Intervention: Control group (unprocessed blood)
Number of subjects: 53
Study 23725103 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived parental attitudes
Number of subjects: 250
Study 20350251 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 50 mg/day
Number of subjects: 1700
Study 20350251 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 20 mg/day
Number of subjects: 1700
Study 20350251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1700
Study 17625985 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI (80/4.5 microg)
Number of subjects: 201
Study 17625985 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol DPI (4.5 microg)
Number of subjects: 201
Study 17625985 — intervention group
Group type: COMPARATOR
Intervention: budesonide pMDI (80 microg) alone
Number of subjects: 201
Study 17625985 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol pMDI and formoterol DPI
Number of subjects: 201
Study 16584339 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal scaling and root planing
Number of subjects: 0
Study 15094102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amino acid mixture (OAAM)
Number of subjects: 0
Study 15094102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11922397 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (PRM) 30 mg
Number of subjects: 20
Study 11922397 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (L-CTZ) 5 mg
Number of subjects: 20
Study 11922397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (CTZ) 10 mg
Number of subjects: 20
Study 11922397 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (LOR) 10 mg
Number of subjects: 20
Study 9517644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 250 mg q.i.d.
Number of subjects: 648
Study 9517644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 648
Study 9517644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.i.d. with clarithromycin 500 mg b.i.d. and metronidazole 400 mg b.i.d. for the first 2 wk
Number of subjects: 648
Study 8050457 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound (DU)
Number of subjects: 25
Study 8050457 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain gauge plethysmography (SGP)
Number of subjects: 25
Study 8050457 — intervention group
Group type: COMPARATOR
Intervention: Various combinations of cuff/strain gauge positioning
Number of subjects: 25
Study 3046814 — intervention group
Group type: EXPERIMENTAL
Intervention: guanabenz
Number of subjects: 218
Study 3046814 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Number of subjects: 218
Study 29701288 — intervention group
Group type: EXPERIMENTAL
Intervention: BAHS implantation using minimally invasive Ponto surgery technique
Number of subjects: 35